Form 4: Artiva R&D SVP Exchanges Options for RSUs
Insider Transaction Report
Artiva Biotherapeutics' SVP of Research and Development, Heather Raymon, exchanged employee stock options for 67,253 restricted stock units.
Summary
- Heather Raymon, SVP of Research and Development at Artiva Biotherapeutics, Inc., engaged in an option exchange on December 12, 2025.
- She acquired 67,253 shares of Common Stock in the form of Restricted Stock Units (RSUs) under the Issuer's 2024 Equity Incentive Plan.
- Concurrently, she disposed of 67,255 employee stock options with various exercise prices ranging from $5.01 to $13.47.
- The options were cancelled as part of the exchange for the RSUs.
- Following the transaction, Raymon beneficially owns 106,844 shares of Common Stock.
- The transaction was made pursuant to a Rule 10b5-1(c) plan.
Sentiment
Score: 6
Explanation: Neutral to slightly positive. The transaction is a routine executive compensation event, converting options to RSUs, which can be seen as a positive for long-term retention and alignment of interests, but doesn't indicate new operational performance.
Positives
- The grant of Restricted Stock Units (RSUs) aligns executive incentives with long-term shareholder value.
- The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-planned transaction and reducing concerns about opportunistic insider trading.
Negatives
- The disposal of employee stock options, while part of an exchange, reduces direct exposure to potential upside from option exercise.
Future Outlook
N/A
Industry Context
N/A
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Incentive Plan | Restricted Stock Units were granted under the Issuer's 2024 Equity Incentive Plan. | December 12, 2025 | Reinforces executive compensation structure and aligns management incentives with shareholder value through long-term equity awards. |
| Power of Attorney | Limited Power of Attorney granted by Heather Raymon to Fred Aslan, Jennifer Bush, and Andrew Cronauer for Section 16(a) filings. | December 12, 2025 | Streamlines the process for filing required SEC forms for the reporting person. |
Related Party Transactions
- The transaction involves an option exchange and RSU grant between Artiva Biotherapeutics, Inc. and Heather Raymon, an SVP of the company, which constitutes a related party transaction in the context of executive compensation.
Stakeholder Impact
- Shareholders: The grant of RSUs aligns executive incentives with long-term shareholder value.
- Employees: Reflects the company's ongoing use of equity incentive plans for key personnel.
Next Steps
- Continued vesting of the newly granted Restricted Stock Units according to their schedule.
Key Dates
| Date | Description |
|---|---|
| October 22, 2021 | Initial vesting date for a portion of the employee stock options that were subsequently cancelled on December 12, 2025. |
| February 22, 2022 | Initial vesting date for a portion of the employee stock options that were subsequently cancelled on December 12, 2025. |
| January 1, 2024 | Initial vesting date for portions of two sets of employee stock options that were subsequently cancelled on December 12, 2025. |
| July 19, 2025 | Initial vesting date for a portion of the employee stock options that were subsequently cancelled on December 12, 2025. |
| December 12, 2025 | Date of the option exchange transaction where employee stock options were cancelled in exchange for Restricted Stock Units. Also the effective date of the Limited Power of Attorney. |
| November 2, 2030 | Expiration date for a set of employee stock options that were cancelled on December 12, 2025. |
| April 2, 2033 | Expiration date for two sets of employee stock options that were cancelled on December 12, 2025. |
| January 23, 2034 | Expiration date for a set of employee stock options that were cancelled on December 12, 2025. |
| May 1, 2034 | Expiration date for a set of employee stock options that were cancelled on December 12, 2025. |
Recommendation
holdThis Form 4 filing details a routine executive compensation event where an SVP exchanged stock options for restricted stock units. While it aligns executive incentives with long-term company performance, it does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a catalyst for significant price movement or a re-evaluation of the company's fundamentals.
Keywords
Artiva Biotherapeutics, ARTV, Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Incentive Plan, Heather Raymon, SVP Research and Development, Option Exchange, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.